Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)
Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight today after the company and its partner Johnson & Johnson announced they will discontinue a major Phase 3 trial of their experimental blood thinner milvexian in acute coronary syndrome (ACS). The decision, based on a scheduled interim review showing the study was unlikely to hit its main goal, has pushed BMY shares lower and reignited